Background The mainstay of atopic dermatitis treatment has been largely unchanged over
the last few decades. With improved understanding of the immunologic pathways underlying …

Background Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and
are often restricted by safety concerns. Biologics may address the unmet need for improved …

Biologic medications are recent advances that have clinical significance in the treatment of
moderate-to-severe AD. A systemic literature review was performed to examine the efficacy …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …

Atopic dermatitis (AD) is a common inflammatory dermatologic disease clinically
characterized by intense itch, recurrent eczematous lesions, and a chronic or relapsing …

Background Systemic medications are often required for severe atopic dermatitis (AD)
refractory to topical therapies. Biologic medications are a recent advancement in the field …

Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the
treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients …

Introduction A comprehensive review of the English-language medical literature was
performed searching for ongoing and closed clinical trials concerning new and emerging …

Phase I and II studies published recently suggest that dupilumab, a monoclonal antibody
that targets a subunit of the interleukin‑4 (IL‑4) and IL‑13 receptors, has the potential to …

• The two most recently Food and Drug Administration–-approved medications are
dupilumab and crisaborole.• There are a number of topical and systemic novel and …